Overview

Registry for Migraine - Clinical Core

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

Phase:

Phase 4

Details

Lead Sponsor:

Danish Headache Center

Treatments:

Erenumab